1 day ago · Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million biobucks to access OncoNano Medicine’s tumor-targeting.
1 day ago · Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million biobucks to access OncoNano Medicine’s tumor-targeting.
